NDA 218637 · Kamat
Raldesy
Trazodone Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Nov 13, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Nov 26, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
71
12 Phase 3, 16 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] . RALDESY is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS and BEHAVIORS See full prescribing information for complete boxed warning. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). RALDESY is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Sep 1, 2026.
RALDESY TM is indicated for the treatment of major depressive disorder (MDD) in adults. RALDESY is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RALDESY · TRAZODONE HYDROCHLORIDE 10MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trazodone" as an intervention, any sponsor and status, largest first.
- A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for InsomniaPivotal-lookingRecruiting
University of PennsylvaniaAcademic, hospital or other
NCT07542756 · 1,200 participants (planned) · Start May 1, 2026 · Primary completion Jan 1, 2032
Drug: Diphenhydramine, 25 mg; Diphenhydramine, 50 mg and 7 more · For: Insomnia; Insomnia Disorder; Chronic Insomnia and 1 more
Sites: Philadelphia, Pennsylvania
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialPivotal-lookingRecruiting
University of EdinburghAcademic, hospital or other
NCT04302870 · 1,150 participants (planned) · Start Feb 27, 2020 · Primary completion Dec 2030
Drug: Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution and 4 more · For: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Sites: Portadown, United Kingdom; Aberdeen, United Kingdom; Birmingham, United Kingdom · 22 sites in all
- Algorithm Guided Treatment Strategies for Major Depressive DisorderPivotal-lookingStatus unknown
Shanghai Mental Health CenterAcademic, hospital or other
NCT01764867 · 1,080 participants (planned) · Start Jun 2012 · Primary completion Oct 2014
Drug: Escitalopram; Mirtazapine and 11 more · For: Major Depressive Disorder
Sites: Shanghai, China
Samsung Medical CenterAcademic, hospital or other
NCT00817011 · 1,000 participants (planned) · Start Apr 2006 · Primary completion Dec 2016
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Antidepressant Drug Adverse Reaction
Sites: Kangnam, South Korea
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia SymptomsPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT07136415 · 1,000 participants (planned) · Start Feb 13, 2026 · Primary completion Feb 2031
Drug: Trazodone; Daridorexant · For: Menopausal Women; Insomnia
Sites: Boston, Massachusetts; Novi, Michigan; Winston-Salem, North Carolina · 5 sites in all
- National Adaptive Trial for PTSD Related InsomniaPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT03668041 · 673 participants · Start Feb 25, 2021 · Primary completion Mar 30, 2026
Drug: Trazodone; Eszopiclone · For: Insomnia
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Phoenix, Arizona · 35 sites in all
- A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and ComorbidityPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT02655354 · 635 participants · Start Oct 2015 · Primary completion Nov 2019
Drug: Fluoxetine; Fluvoxamine and 9 more · For: Posttraumatic Stress Disorder; Depression; Alcohol-Related Disorders and 8 more
Sites: Scottsdale, Arizona; Beverly Hills, California; Sacramento, California · 24 sites in all
- Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in InsomniaPivotal-lookingRecruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT06281756 · 600 participants (planned) · Start Mar 20, 2024 · Primary completion Nov 30, 2027
Drug: Trazodone · For: Insomnia; Insomnia Chronic; Insomnia, Primary and 2 more
Sites: Denver, Colorado; Hershey, Pennsylvania; Pittsburgh, Pennsylvania · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, et al. · Lancet 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.
Gerolymos C, Barazer R, Yon DK, et al. · JAMA Netw Open 2024 · Systematic Review, Network Meta-Analysis
- Dystonia.
Snaith A, Wade D · BMJ Clin Evid 2014 · Systematic Review
- Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis.
Kokkali M, Pinioti E, Lappas AS, et al. · CNS Drugs 2024 · Systematic Review, Meta-Analysis
- Interactions between herbal medicines and prescribed drugs: an updated systematic review.
Izzo AA, Ernst E · Drugs 2009 · Systematic Review
Sponsor: Kamat
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.